1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Advances in Monoclonal Antibody Therapeutics 

Advances in Monoclonal Antibody Therapeutics 

  • September 2015
  • -
  • Frost & Sullivan
  • -
  • 94 pages

Advances in monoclonal antibody therapeutics

Monoclonal antibody therapeutics are being used for treatment of a wide array of diseases, specially in therapeutic areas such as oncology, immunology (including autoimmune and inflammatory diseases, as well as, transplant rejection) and neuroscience. The development of these new molecular agents, successfully directed to specific cellular targets, is playing a crucial role in the pharmaceutical industry. This trend shows the strong focus of top biopharmaceutical companies in biologics, including monoclonal antibody therapeutics. This research service discusses the emerging trends in monoclonal antibody therapeutics on a global scale, through a detailed strategic assessment of the industry environment.

Key Findings

Next-generation products are expected to be superior to first-generation products, in terms of potency against disease targets, ability to treat more than one aspect of a disease simultaneously, better and cheaper production processes and fewer side effects.

Big Pharma companies (Amgen, Novartis, Pfizer, Roche), are advancing through deals with potentially very large payoffs to acquire antibody technologies, compensating some patent losses in more traditional molecules and making easier to afford the advent of biosimilars.

Nanobodies (Ablynx), stapled peptides (Aileron), single-gene mutation gene therapy (BlueBird Bio), neurotrophic factor gene therapy (Sangamo BioSciences), Dicer-substrate short interfering RNAs (Dicerna), therapeutic vaccines (Galena), dual-affinity re-targeting (MacroGenics), bispecific T-cell engaging antibodies (Amgen), locked nucleic acids (Roche), and XmAbs (Xencor), are highlighted.

Although immuno-modulatory antibodies have also recently achieved remarkable clinical success, regulatory issues in biologics plays a crucial role in the development of monoclonal antibody therapeutics.

A profound knowledge of the molecular basis of the disease, as well as, outstanding protein-engineering techniques, mechanisms of action and resistance, including the behavior exhibited by the immune system and the targeted cells is essential. In terms of therapeutic areas, the use of monoclonal antibodies in immuno-oncology has achieved considerable success in recent years. Antibody–drug conjugates are powerful new treatment options for lymphomas and solid tumors. Principal deals are strongly correlated to immuno-oncology areas.

Table Of Contents

Advances in Monoclonal Antibody Therapeutics 
1 EXECUTIVE SUMMARY

Executive Summary
1 Research Scope
2 Research Methodology
3 Key Findings

2 MONOCLONAL ANTIBODIESA SNEAK PREVIEW

Monoclonal AntibodiesA Sneak Preview
1 Technology Snapshot - Multiple Segmentation
2 Industry Overview - Main Innovations
3 Industry Overview - Main Innovators
4 Technology Roadmap Toward Precision Medicine

3 STRATEGIC ASSESSMENT OF THE INDUSTRY ENVIRONMENT

Strategic Assessment of the Industry Environment
1 Therapeutic Areas and Clinical Indications
2 Molecular Agents and Cell Targets
3 Developmental Stage Focus
4 Market Potential
5 Market Evolution
6 Venture Capital Investment
7 Company Stage Investment Focus
8 Government Funding and Support
9 Worldwide Landscape
10 Key Drivers and Restraints
11 Key Technical and Business Challenges

4 INDUSTRY BEST PRACTICES AND STRATEGIC INSIGHTS

Industry Best Practices and Strategic Insights
1 Industry Assessment - Partnerships and Alliances
2 Stakeholder Assessment for Partnerships
3 Partnerships and Alliances Models
4 Partnerships and Collaborations
5 Partnerships and Collaborations
6 Partnerships and Collaborations
7 Patent Analysis
8 Patent publishing trends
9 Patent office-wise distribution

5 STRATEGIC EVALUATION OF RandD PORTFOLIO

Strategic Evaluation of RandD Portfolio
1 RandD Success and Key Performance Indicators
2 Analytical Hierarchy Process (AHP)
3 Analytical Hierarchy Process (AHP)
4 Analytical Hierarchy Process (AHP)
5 Analytical Hierarchy Process (AHP)
6 Analytical Hierarchy Process (AHP)
7 Analytical Hierarchy Process (AHP)
8 Analytical Hierarchy Process (AHP)
9 Analytical Hierarchy Process (AHP)
10 Analytical Hierarchy Process (AHP)

6 KEY CONTACTS

Key Contacts
1 Contacts
2 Contacts

7 APPENDIX

Appendix
1 Strategic RandD Pipeline - The Road Ahead
2 RandD Pipeline Assessment
3 RandD Pipeline Assessment
4 RandD Pipeline Assessment
5 RandD Pipeline Assessment
6 RandD Pipeline Assessment
7 RandD Pipeline Assessment
8 RandD Pipeline Assessment
9 RandD Pipeline Assessment
10 RandD Pipeline Assessment
11 RandD Pipeline Assessment
12 RandD Pipeline Assessment
13 RandD Pipeline Assessment
14 RandD Pipeline Assessment
15 RandD Pipeline Assessment
16 RandD Pipeline Assessment
17 RandD Pipeline Assessment
18 RandD Pipeline Assessment
19 RandD Pipeline Assessment
20 RandD Pipeline Assessment
21 RandD Pipeline Assessment
22 RandD Pipeline Assessment
23 RandD Pipeline Assessment
24 RandD Pipeline Assessment
25 RandD Pipeline Assessment
26 RandD Pipeline Assessment
27 Product Line Assessment
28 Product Line Assessment
29 Product Line Assessment
30 Product Line Assessment
31 Product Line Assessment
32 Product Line Assessment
33 Product Line Assessment
34 Product Line Assessment
35 Product Line Assessment
36 Product Line Assessment
37 Abbreviations
38 Legal Disclaimer

8 THE FROST and SULLIVAN STORY

The Frost and Sullivan Story
1 The Frost and Sullivan Story
2 Value Proposition: Future of Your Company and Career
3 Global Perspective
4 Industry Convergence
5 360º Research Perspective
6 Implementation Excellence
7 Our Blue Ocean Strategy

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

R&D Drug Pipeline Database: 1-Year Subscription

R&D Drug Pipeline Database: 1-Year Subscription

  • $ 6600
  • Industry report
  • November 2016
  • by La Merie Publishing

R&D Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.